Abstract
Despite advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been approved by the US Food and Drug Administration to treat EoE. Off-label, EoE is currently treated by using the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic dilation. In the recent past, considerable progress in terms of EoE treatment has been made: (1) new EoE-specific steroid formulations optimizing mucosal deposition have been developed, which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other TH2-mediated diseases, such as allergic asthma and atopic eczema, as well as purpose-developed biologics, have been studied in phase II trials in patients with EoE; and (3) novel dietary restriction strategies have evolved. Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article we will discuss recent advances in EoE treatment with regard to swallowed topical steroids, biological agents, dietary approaches, and novel molecular targets.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 38-45 |
| Number of pages | 8 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 145 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2020 |
Fingerprint
Keywords
- Eosinophilic esophagitis
- biologics
- diet
- steroids
- treatment
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
}
Emerging therapies for eosinophilic esophagitis. / Greuter, Thomas; Hirano, Ikuo; Dellon, Evan S.
In: Journal of Allergy and Clinical Immunology, Vol. 145, No. 1, 01.2020, p. 38-45.Research output: Contribution to journal › Article
TY - JOUR
T1 - Emerging therapies for eosinophilic esophagitis
AU - Greuter, Thomas
AU - Hirano, Ikuo
AU - Dellon, Evan S.
PY - 2020/1
Y1 - 2020/1
N2 - Despite advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been approved by the US Food and Drug Administration to treat EoE. Off-label, EoE is currently treated by using the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic dilation. In the recent past, considerable progress in terms of EoE treatment has been made: (1) new EoE-specific steroid formulations optimizing mucosal deposition have been developed, which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other TH2-mediated diseases, such as allergic asthma and atopic eczema, as well as purpose-developed biologics, have been studied in phase II trials in patients with EoE; and (3) novel dietary restriction strategies have evolved. Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article we will discuss recent advances in EoE treatment with regard to swallowed topical steroids, biological agents, dietary approaches, and novel molecular targets.
AB - Despite advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been approved by the US Food and Drug Administration to treat EoE. Off-label, EoE is currently treated by using the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic dilation. In the recent past, considerable progress in terms of EoE treatment has been made: (1) new EoE-specific steroid formulations optimizing mucosal deposition have been developed, which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other TH2-mediated diseases, such as allergic asthma and atopic eczema, as well as purpose-developed biologics, have been studied in phase II trials in patients with EoE; and (3) novel dietary restriction strategies have evolved. Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article we will discuss recent advances in EoE treatment with regard to swallowed topical steroids, biological agents, dietary approaches, and novel molecular targets.
KW - Eosinophilic esophagitis
KW - biologics
KW - diet
KW - steroids
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85075516527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075516527&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2019.10.027
DO - 10.1016/j.jaci.2019.10.027
M3 - Article
C2 - 31705907
AN - SCOPUS:85075516527
VL - 145
SP - 38
EP - 45
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 1
ER -